GlassScriptPhysician profile
Amena Iqbal
NPI 1124469523
$7,561.72
in general payments reported to CMS, 2019-2025
43 companies · $991 in 2025
The $991 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $814 · 2021: $979 · 2022: $1,340 · 2023: $963 · 2024: $732 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,450.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $544.28 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $510.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Tandem Diabetes Care, INC. | $452.31 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $370.47 | 2019-2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $342.06 | 2019-2022 | |
| Dexcom, INC. | $332.85 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $286.71 | 2019-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $270.38 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $264.29 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.12 | 2022-2025 | |
| Abbvie INC. | $242.82 | 2019-2025 | |
| Horizon Therapeutics Plc | $235.56 | 2019-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $221.66 | 2019-2024 | |
| Amgen INC. | $202.21 | 2019-2025 | Tepezza, Evenity |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amena Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.